SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

Mankind Pharma

BSE: 543904 22 Aug 2025
Healthcare
₹ 2610
Mankind Pharma Limited specializes in Pharmaceuticals within the Healthcare sector.

Mankind Pharma - Share Price & Details

Market Cap
₹1,07,314
High /Low
3,055 / 2,115
Stock P/E
56.8
Book Value
₹347.0
Dividend Yield
0.04
ROCE
16.0
ROE
₹14.7
Face Value
1.0
PEG Ratio
6.86
EVEBITDA
₹30.9
Debt
8,511
CMP / FCF
69.2
Debt to equity
₹0.59
NP Ann
2,011
High price all time
3,055
Piotroski score
₹4.0
Graham Number
602.0
No. Eq. Shares
41.3
Net CF
₹21.9
Net profit
1,913
Price to book value
7.48
Interest Coverage
₹5.06
Low price all time
1,241
Industry PE
32.8
Reserves
₹14,291
Free Cash Flow
₹1,895

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
Shyama Computronics and Servic1.480.930.670.005.3335.5
Triochem Products Ltd.,3.25-4.52NA-18.440
Mankind Pharma Limited26055.84127.625413.69.991,07,31456.8
DR.REDDYS LABORATORIES LTD.88624.014099.085721.017.0210666418.8
Zydus Lifesciences Limited27454.03847.025883.03.829958221.4

Peer Comparison Chart


About Mankind Pharma

Mankind Pharma Limited, with Security Code 543904, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

7 Best Derma Companies in India Offering PCD Pharma Franchise Opportunities

(13 Aug 2025)
Start your derma PCD franchise with India's top skincare pharma companies. Explore Gary Pharma, Mankind, Glenmark & more.
Read more →

Mankind Pharma Q1FY25-26: Strong Volume Recovery Drives 25% Revenue Growth

(12 Aug 2025)
Mankind Pharma Limited (Mankind) reported a strong operational comeback in Q1FY25-26, with revenues jumping 24% to Rs3,570 crore, marking the company's...
Read more →

Divi's Lab, Mankind Pharma among 7 largecap stocks below their 200 DMAs

(11 Aug 2025)
In the NSE large-cap pack, seven stocks' closing prices fell below their 200-day moving averages (200 DMA) on August 8, according to...
Read more →

Mankind Pharma Confident GLP-1 Wont Dent Anti-Diabetic Portfolio Growth

(09 Aug 2025)
Mankind Pharma Ltd. remains confident that the rise of GLP-1 therapies will not materially impact its anti-diabetic portfolio,...
Read more →

Mankind Pharma Limited: Unlocking Growth in a Fragmented Indian Pharma Market

(08 Aug 2025)
Mankind Pharma leads India's fragmented pharma market via chronic therapy focus (37.1% portfolio) and consumer brands like Manforce,...
Read more →

IOC, Hindalco, MCX, Mankind Pharma, ABB India to turn ex-dividend on Friday

(08 Aug 2025)
The IOC board, at its meeting held on April 30, had recommended a final dividend of Rs 3 per equity share of a face value of Rs 10 each for...
Read more →

Company Updates